These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21497435)

  • 1. Small renal mass and low-risk prostate cancer: any more for active surveillance?
    Yates DR; Rouprêt M
    Eur Urol; 2011 Jul; 60(1):45-7. PubMed ID: 21497435
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
    Klotz L
    Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
    [No Abstract]   [Full Text] [Related]  

  • 3. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
    Dall'Era MA; Konety BR
    Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal tumor natural history: the rationale and role for active surveillance.
    Jewett MA; Zuniga A
    Urol Clin North Am; 2008 Nov; 35(4):627-34; vii. PubMed ID: 18992616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
    Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
    J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance for favorable risk prostate cancer: rationale, risks, and results.
    Klotz L
    Urol Oncol; 2007; 25(6):505-9. PubMed ID: 18047961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
    J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    van den Bergh RC; Essink-Bot ML; Roobol MJ; Schröder FH; Bangma CH; Steyerberg EW
    J Urol; 2010 May; 183(5):1786-91. PubMed ID: 20299064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance for prostate cancer in a veteran population.
    Lee EK; Baack J; Penn H; Bromfield CT; Duchene DA; Thrasher JB; Holzbeierlein JM
    Can J Urol; 2010 Dec; 17(6):5429-35. PubMed ID: 21172105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D; Lindner A; Stay K; Zisman A
    Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?
    Schmidt C
    J Natl Cancer Inst; 2010 Oct; 102(20):1533-5. PubMed ID: 20935269
    [No Abstract]   [Full Text] [Related]  

  • 16. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
    Abouassaly R; Lane BR; Jones JS
    Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
    Ploussard G; Durand X; Xylinas E; Moutereau S; Radulescu C; Forgue A; Nicolaiew N; Terry S; Allory Y; Loric S; Salomon L; Vacherot F; de la Taille A
    Eur Urol; 2011 Mar; 59(3):422-9. PubMed ID: 21156337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
    J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological outcomes of candidates for active surveillance of prostate cancer.
    Conti SL; Dall'era M; Fradet V; Cowan JE; Simko J; Carroll PR
    J Urol; 2009 Apr; 181(4):1628-33; discussion 1633-4. PubMed ID: 19233388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance of small renal masses: progression patterns of early stage kidney cancer.
    Jewett MA; Mattar K; Basiuk J; Morash CG; Pautler SE; Siemens DR; Tanguay S; Rendon RA; Gleave ME; Drachenberg DE; Chow R; Chung H; Chin JL; Fleshner NE; Evans AJ; Gallie BL; Haider MA; Kachura JR; Kurban G; Fernandes K; Finelli A
    Eur Urol; 2011 Jul; 60(1):39-44. PubMed ID: 21477920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.